Global Mice Model Market is poised to depict significant growth from 2023 to 2032 owing to the rising demand for humanized mice models.

Humanized mice are increasingly being used as models for biomedical research applications, such as infectious diseases, HIV/AIDS, cancer, hepatitis, and regenerative medicine. Humanized mice models are an essential tool for conducting preclinical research to expand insights into human biology. Increasing preclinical studies will supplement the mice model market.


Furthermore, the growing consumption of personalized medicine in developing and developed countries is estimated to propel the market growth. Precision medicines are used and prescribed in clinics and hospitals, especially for cancer and neurodegenerative disorders. Humanized mouse models are recommended to treat cancer by offering personalized precision medicines, thus, creating an optimistic growth outlook for the mice model industry.


The mice model market is segmented based on type, technology application, end-use, and region.


The hybrid mice model segment held more than 17% revenue share in 2022 and is estimated to grow at an appreciable CAGR through 2032. Hybrid mice are the offspring of two different parents and tend to be stronger than the parental strains, with longer lifespans and fewer incidences of strain-specific pathologies. The rising use of hybrid mice for research operations will supplement the market growth.


Microinjection technology is expected to gain significant popularity over 2023-2032 due to its effectiveness and versatility in creating genetically engineered mice. Furthermore, this technology allows for the insertion of DNA into each cell of growing mice with a great potential for regeneration. In addition, substantial advancements in microinjection methods will contribute to a higher acceptance of this technology, thereby driving market expansion.


The mice model market from the production and quality control application segment is estimated to grow substantially from 2023 to 2032 propelled by the high demand for mice models to test the safety of vaccines such as malaria and tuberculosis. Additionally, the growing inclination towards personalized medicines and targeted therapy to treat cancer patients has also led to higher production and quality control checks, thereby boosting segment revenue.

As per end-use, the mice model industry from the academic and research institutes segment could record robust growth owing to the increasing number of academic and research institutes across the globe. High adoption of mice models for understanding the biological behavior and mechanism of diseases, in line with the ongoing preclinical trials requiring mice models for precision medicines, will contribute to segment growth.

The mice model market in the Asia Pacific is expected to exhibit over 6.5% CAGR over 2023-2032 owing to the continuous increase in the population suffering from chronic disorders. The growing disease burden is stimulating the demand for effective therapeutics resulting in an increase in the number of R&D laboratories in the region. Several regional players are investing in expanding the demand for mice models in the region, which could support industry growth through 2032.